相似文献
1
Patients with COVID-19 and neurological manifestations show undetectable SARS-CoV-2 RNA levels in the cerebrospinal fluid.
Int J Infect Dis. 2020 Jul;96:567-569. doi: 10.1016/j.ijid.2020.05.123. Epub 2020 Jun 4.
2
Neurological manifestations in COVID-19 caused by SARS-CoV-2.
CNS Neurosci Ther. 2020 May;26(5):499-501. doi: 10.1111/cns.13372. Epub 2020 Apr 7.
3
Report of a patient with neurological symptoms as the sole manifestation of SARS-CoV-2 infection.
Neurologia (Engl Ed). 2020 May;35(4):271-272. doi: 10.1016/j.nrl.2020.04.010. Epub 2020 Apr 24.
4
Understanding the neurotropic characteristics of SARS-CoV-2: from neurological manifestations of COVID-19 to potential neurotropic mechanisms.
J Neurol. 2020 Aug;267(8):2179-2184. doi: 10.1007/s00415-020-09929-7. Epub 2020 May 26.
5
[COVID-19: A neurological point-of-view].
Dtsch Med Wochenschr. 2020 Jul;145(15):1074-1079. doi: 10.1055/a-1164-4323. Epub 2020 Jul 30.
6
Lifting the mask on neurological manifestations of COVID-19.
Nat Rev Neurol. 2020 Nov;16(11):636-644. doi: 10.1038/s41582-020-0398-3. Epub 2020 Aug 24.
7
Acute necrotizing encephalopathy with SARS-CoV-2 RNA confirmed in cerebrospinal fluid.
Neurology. 2020 Sep 8;95(10):445-449. doi: 10.1212/WNL.0000000000010250. Epub 2020 Jun 25.
8
Does immune privilege result in recovered patients testing positive for COVID-19 again?
Biosci Trends. 2020 Jul 17;14(3):209-211. doi: 10.5582/bst.2020.03154. Epub 2020 May 16.
9
The neurological impact of COVID-19.
Lancet Neurol. 2020 Jun;19(6):471. doi: 10.1016/S1474-4422(20)30142-3. Epub 2020 May 26.
10
Neurotropism of SARS-CoV 2: Mechanisms and manifestations.
J Neurol Sci. 2020 May 15;412:116824. doi: 10.1016/j.jns.2020.116824. Epub 2020 Apr 8.
引用本文的文献
1
Central nervous system and systemic inflammatory networks associated with acute neurological outcomes in COVID-19.
Sci Rep. 2025 Jul 6;15(1):24154. doi: 10.1038/s41598-025-08632-9.
2
Comparison of cerebrospinal fluid biomarkers in patients with severe COVID-19 neurological outcomes and Alzheimer's disease.
Brain Behav Immun Health. 2025 Apr 30;46:101007. doi: 10.1016/j.bbih.2025.101007. eCollection 2025 Jul.
3
Neuropsychiatric Burden of SARS-CoV-2: A Review of Its Physiopathology, Underlying Mechanisms, and Management Strategies.
Viruses. 2024 Nov 21;16(12):1811. doi: 10.3390/v16121811.
4
Acute Encephalopathies in SARS-CoV-2 Infection: A Clinical and Neuroimaging Perspective.
Adv Exp Med Biol. 2024;1457:125-141. doi: 10.1007/978-3-031-61939-7_7.
5
Changes in neuroinflammatory biomarkers correlate with disease severity and neuroimaging alterations in patients with COVID-19 neurological complications.
Brain Behav Immun Health. 2024 Jun 13;39:100805. doi: 10.1016/j.bbih.2024.100805. eCollection 2024 Aug.
6
From Detection to Protection: Antibodies and Their Crucial Role in Diagnosing and Combatting SARS-CoV-2.
Vaccines (Basel). 2024 Apr 25;12(5):459. doi: 10.3390/vaccines12050459.
7
[Neurological complications in critical patients with COVID-19].
Neurologia. 2020 Nov-Dec;35(9):621-627. doi: 10.1016/j.nrl.2020.07.014. Epub 2020 Aug 4.
8
[Myopathy associated with severe SARS-CoV-2 infection].
Neurologia. 2020 Nov-Dec;35(9):706-708. doi: 10.1016/j.nrl.2020.07.003. Epub 2020 Jul 21.
9
Neurological complications after COVID-19: A narrative review.
eNeurologicalSci. 2023 Nov 15;33:100485. doi: 10.1016/j.ensci.2023.100485. eCollection 2023 Dec.
10
COVID-19 and Alzheimer's Disease Share Common Neurological and Ophthalmological Manifestations: A Bidirectional Risk in the Post-Pandemic Future.
Cells. 2023 Nov 10;12(22):2601. doi: 10.3390/cells12222601.
本文引用的文献
1
Steroid-Responsive Encephalitis in Coronavirus Disease 2019.
Ann Neurol. 2020 Aug;88(2):423-427. doi: 10.1002/ana.25783. Epub 2020 Jun 9.
2
Facial diplegia, a possible atypical variant of Guillain-Barré Syndrome as a rare neurological complication of SARS-CoV-2.
J Clin Neurosci. 2020 Jul;77:230-232. doi: 10.1016/j.jocn.2020.05.016. Epub 2020 May 14.
3
Early Guillain-Barré syndrome in coronavirus disease 2019 (COVID-19): a case report from an Italian COVID-hospital.
Neurol Sci. 2020 Jun;41(6):1351-1354. doi: 10.1007/s10072-020-04449-8. Epub 2020 May 12.
4
Plasmapheresis treatment in COVID-19-related autoimmune meningoencephalitis: Case series.
Brain Behav Immun. 2020 Jul;87:155-158. doi: 10.1016/j.bbi.2020.05.022. Epub 2020 May 7.
5
SARS-CoV-2: "Three-steps" infection model and CSF diagnostic implication.
Brain Behav Immun. 2020 Jul;87:128-129. doi: 10.1016/j.bbi.2020.05.002. Epub 2020 May 5.
6
Two patients with acute meningoencephalitis concomitant with SARS-CoV-2 infection.
Eur J Neurol. 2020 Sep;27(9):e43-e44. doi: 10.1111/ene.14298. Epub 2020 May 30.
7
SARS-CoV-2 can induce brain and spine demyelinating lesions.
Acta Neurochir (Wien). 2020 Jul;162(7):1491-1494. doi: 10.1007/s00701-020-04374-x. Epub 2020 May 4.
8
Guillain-Barré syndrome as a complication of SARS-CoV-2 infection.
Brain Behav Immun. 2020 Jul;87:111-112. doi: 10.1016/j.bbi.2020.04.074. Epub 2020 Apr 28.
9
Status of SARS-CoV-2 in cerebrospinal fluid of patients with COVID-19 and stroke.
J Neurol Neurosurg Psychiatry. 2020 Aug;91(8):846-848. doi: 10.1136/jnnp-2020-323522. Epub 2020 Apr 30.
10
Guillain-Barré syndrome related to COVID-19 infection.
Neurol Neuroimmunol Neuroinflamm. 2020 Apr 29;7(4). doi: 10.1212/NXI.0000000000000741. Print 2020 Jul.
Zotero 插件